AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01628549
Drug: 100 mg P005672-HCl
RxNorm normalized name: tetracycline hydrochloride 100 MG
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P005672-HCl administered as an oral capsule(s) once daily
Trial: NCT03368391
Drug: 2% Lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
Trial: NCT03368391
Drug: 3% Mepivacaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
Trial: NCT03368391
Drug: saline intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL intranasal saline will be administered as a placebo
Trial: NCT03368391
Drug: saline infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo
Trial: NCT02351167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00547625
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
Trial: NCT03078257
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Trial: NCT00446784
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01085578
Drug: CG400549/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
Trial: NCT01085578
Drug: CG400549/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
Trial: NCT01085578
Drug: CG400549
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
Trial: NCT04478526
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
Trial: NCT00446784
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02828566
Drug: IN saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 0.9% normal saline
Trial: NCT02828566
Drug: IV saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% normal saline
Trial: NCT01737541
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04398134
Drug: ABI-H2158
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 100 mg tablets for oral administration
Trial: NCT04398134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the ABI-H2158 tablets
Trial: NCT02992548
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01529554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
Trial: NCT04009876
Drug: nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Trial: NCT03419962
Drug: MaxSpiolto® Respimat® 160 Characters...
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as per the approved SmPC
Trial: NCT00915187
Drug: CCS/C
RxNorm normalized name: Calcium Carbonate/Calcium Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant to influenza vaccine
Trial: NCT00248092
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01386125
Drug: Placebo for MFNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sprays in each nostril BID for up to 16 weeks
Trial: NCT01781234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00721955
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine Placebo, may repeat after 2 hours x 2
Trial: NCT01928615
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy for early breast cancer.
Trial: NCT00515216
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00136656
Drug: antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
Trial: NCT02459886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03281096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill manufactured to mmic Berberine hydrochloride 100mg tablet
Trial: NCT01828437
Drug: Pyridoxine plus prednisolone
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01828437
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00344045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
Trial: NCT00875082
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
Trial: NCT00006124
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02798419
Drug: DFD05 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004196
Drug: Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02767947
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream will be applied per schedule specified in the arm.
Trial: NCT02994290
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
Trial: NCT04253236
Drug: RVT-1401 680 mg/weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
Trial: NCT02846233
Drug: GLP1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide or Dulaglutide will be added to a basal insulin.
Trial: NCT01896505
Drug: KCP-330
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185963
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg once a daily for 12 weeks
Trial: NCT01327521
Drug: CT Contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT01327521
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00559741
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00559741
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03743259
Drug: LuminoMark inj. 0.1mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
Trial: NCT03743259
Drug: LuminoMark inj. 0.2mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Trial: NCT03743259
Drug: Charcotrace Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Trial: NCT04606017
Drug: Caltrate Pill
RxNorm normalized name: Caltrate Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
Trial: NCT00597428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg capsules twice daily (BID)
Trial: NCT00170144
Drug: Branchamin 4%
RxNorm normalized name: BranchAmin 4% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03785691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Trial: NCT02269735
Drug: MK-2640
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2640 intravenous infusion administered to participant in a fasted state
Trial: NCT02269735
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
Trial: NCT00230191
Drug: RK-0202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243152
Drug: Placebo (for Lamotrigine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Lamotrigine tablets
Trial: NCT01149824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692366
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule~Route of administration: oral
Trial: NCT00668096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03079388
Drug: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
Trial: NCT03079388
Drug: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
Trial: NCT03079388
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
Trial: NCT03915561
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
Trial: NCT00497679
Drug: AZD1152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous intravenous infusion
Trial: NCT01643434
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (titrating dose from 12.5 to 50mg SID)
Trial: NCT02497235
Drug: [18F]MNI-792 (tracer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]MNI-792 injection.
Trial: NCT02342041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01291641
Drug: HMG-CoA Reductase Inhibitor
RxNorm normalized name: HMG-CoA reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor
Trial: NCT02247518
Drug: Cialis Tab. 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247518
Drug: Harnal-D Cap. 0.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00865124
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg capsule daily for 6 months
Trial: NCT00865124
Drug: Hydrochlorothiazide + potassium
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
Trial: NCT03815331
Drug: Xiaflex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
Trial: NCT00742534
Drug: Intravenous L-Citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
Trial: NCT04810533
Drug: [14C] SH-1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
Trial: NCT02377388
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
Trial: NCT02653729
Drug: Espidone
RxNorm normalized name: Equidone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02653729
Drug: Olepra
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393481
Drug: MAA868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAA868 dose 1 and dose 2, single administration, subcutaneous,
Trial: NCT00769314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg muco-adhesive buccal tablets, single application on the gum
Trial: NCT01417273
Drug: Drug: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cap placebo/day for 12 month
Trial: NCT00005970
Drug: Aromatase Inhibition Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00005970
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005970
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00706719
Drug: 25 mg Androxal
RxNorm normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Androxal capsules, 1 capsule daily for 6 months
Trial: NCT01694589
Drug: LDE-225
RxNorm normalized name: LANCET,STERILANCE LDE 2 DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
Trial: NCT00331279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills in likeness of the cinnamon extract
Trial: NCT00041327
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV on day 5
Trial: NCT00041327
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2/day as a continuous 96-hour infusion days 1-4
Trial: NCT02998541
Drug: SHP640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Trial: NCT02998541
Drug: PVP-I 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Trial: NCT02769325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline, 10 ml
Trial: NCT02769325
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
Trial: NCT02576717
Drug: RPC1063
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00633698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
Trial: NCT01040273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00137046
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Trial: NCT00137046
Drug: Inhaled Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Trial: NCT03171324
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day elemental iron
Trial: NCT01984606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching empagliflozin
Trial: NCT01984606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching sitagliptin
Trial: NCT03733587
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500mg/vial
Trial: NCT01913054
Drug: Fentanyl Injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01746654
Drug: P128-0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Trial: NCT01746654
Drug: P128-0.3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Trial: NCT01746654
Drug: P128-1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
Trial: NCT01746654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
Trial: NCT01658995
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.